Repligen
Repligen | Inspiring Advances in Bioprocessing.
Launch date
Employees
Market cap
€7.2b
Enterprise valuation
€7.2b (Public information from Sep 2024)
Share price
$145.78 RGEN
Waltham Massachusetts (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 366m | 671m | 802m | 639m | 627m | 709m | 824m |
% growth | 36 % | 83 % | 20 % | (20 %) | (2 %) | 13 % | 16 % |
EBITDA | 69.6m | 172m | 185m | 92.1m | 108m | 154m | 203m |
% EBITDA margin | 19 % | 26 % | 23 % | 14 % | 17 % | 22 % | 25 % |
Profit | 59.9m | 128m | 186m | 41.6m | 27.3m | 67.6m | 101m |
% profit margin | 16 % | 19 % | 23 % | 7 % | 4 % | 10 % | 12 % |
EV / revenue | 27.2x | 21.5x | 11.3x | 14.7x | 13.1x | 11.4x | 9.7x |
EV / EBITDA | 143.3x | 83.8x | 49.1x | 101.5x | 75.8x | 52.4x | 39.3x |
R&D budget | 20.2m | 34.3m | 43.9m | 42.7m | - | - | - |
R&D % of revenue | 6 % | 5 % | 5 % | 7 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | $1.4m | Grant | |
N/A | $4.0m | Post IPO Equity | |
* | N/A | $175m | Post IPO Equity |
* | N/A | $312m | Post IPO Equity |
* | N/A | $600m | Post IPO Convertible |
Total Funding | €1.3m |
Recent News about Repligen
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Repligen
EditACQUISITION by Repligen Jul 2024
ACQUISITION by Repligen Dec 2016
ACQUISITION by Repligen Jun 2017
ACQUISITION by Repligen Apr 2016
ACQUISITION by Repligen Sep 2021
ACQUISITION by Repligen Nov 2020
ACQUISITION by Repligen Sep 2023
ACQUISITION by Repligen Jun 2021